Burkitt lymphoma

CRANBURY, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, announced a publication on its Phase 2 clinical…

CODOX-M and IVAC regimens have proved effective for the treatment of sporadic BL. But, these standard regimens are short-term and intensive, which frequently causes high toxicity and severe, sometimes life-threatening complications, which…